Condition: Biliary Tract Cancer · Sponsor: UNICANCER
The object of this trial is to test whether ivonescimab is superior to standard chemotherapy (FOLFOX regimen) for the treatment of patients with advanced biliary tract cancer after failure of a first line of chemotherapy. It is only open to patients who participated in the SAFIR-ABC10 trial (NCT05615818) but did not receive experimental treatment. Eligible patients will be randomised (2:1) to receive either ivonescimab or FOLFOX. Treatment will be continued until disease progression, or a maximum of 34 cycles of ivonescimab (experimental arm), whichever occurs first.
This description comes directly from the study's public registry record.
Daniel Couch · +33 (0)1 80 50 12 96 · d-couch@unicancer.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens Picardie | Amiens, France | Recruiting |
| Institut de cancerologie de l'Ouest - Angers | Angers, France | Not Yet Recruiting |
| Institut du Cancer Avignon Provence | Avignon, France | Recruiting |
| CHU Besançon | Besançon, France | Not Yet Recruiting |
| CHU de Bordeaux - Hôpital Haut-Leveque | Bordeaux, France | Not Yet Recruiting |
| Centre François Baclesse | Caen, France | Not Yet Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| CHU Estaing de Clermont Ferrand | Clermont-Ferrand, France | Not Yet Recruiting |
| APHP - Hôpital Beaujon | Clichy, France | Recruiting |
| APHP - Hopital Henri Mondor | Créteil, France | Not Yet Recruiting |
| CHU de Dijon | Dijon, France | Recruiting |
| Groupe hospitalier mutaliste de Grenoble - Institut Daniel Hollard | Grenoble, France | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06529718